State Street Corp has increased its stake in Taysha Gene Therapies, Inc. by 4.5% during the third quarter of 2024, now owning 3,469,068 shares after acquiring an additional 150,647 shares.

The company currently has a market capitalization of approximately $358.65 million, a price-to-earnings ratio of 2.78, and a beta of 0.78.

As of December 27, 2024, Taysha Gene Therapies shares opened at $1.75, with a 12-month trading range from $1.19 to $4.32.

Earlier, on December 18, 2024, the stock opened at $2.03, reflecting its volatility within the past year.

Equities research analysts have expressed positive outlooks for Taysha Gene Therapies, with several firms setting price targets between $5.00 and $8.00, leading to a consensus target price of $6.63.

Other institutional investors, including Creative Planning, Principal Financial Group, and China Universal Asset Management, have also adjusted their holdings in Taysha Gene Therapies, making significant investments in the second and third quarters of 2024.

China Universal Asset Management Co. Ltd. notably raised its stake by 79.4%, now holding 39,417 shares valued at $79,000 after purchasing 17,446 shares in the last quarter.

Taysha Gene Therapies specializes in developing gene therapies for monogenic diseases affecting the central nervous system, with several products in development targeting conditions like giant axonal neuropathy and Rett syndrome.

Chardan Capital has maintained a 'buy' rating for Taysha Gene Therapies with a target price of $7.00 as of November 14, 2024.

Institutional investors and hedge funds collectively own a significant 77.70% of Taysha Gene Therapies' stock, indicating strong institutional interest.

Charles Schwab's stake in Taysha Gene Therapies is valued at approximately $930,000, representing about 0.23% of the company's total shares.